Asset Details
Do you wish to reserve the book?
Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass
Do you wish to request the book?
Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass
2025
Overview
Summary
We investigated the efficacy of romosozumab in premenopausal women with low bone mass. Romosozumab substantially increased bone mineral density and trabecular bone score in these women, aligning with its proven therapeutic benefits for postmenopausal osteoporosis.
Purpose
Romosozumab, an anti-sclerostin antibody, is a promising anabolic agent that increases bone formation and decreases bone resorption. However, its efficacy in premenopausal women with low bone mass remains understudied.
Methods
We retrospectively reviewed premenopausal women with low bone mass treated with romosozumab (ROMO group) or drug-naïve patients (control group). Patients in the ROMO group were classified into the glucocorticoid-induced osteoporosis (GIOP), idiopathic osteoporosis (IOP), and pregnancy and lactation-induced osteoporosis (PLO) subgroups. Bone mineral density (BMD) and trabecular bone score (TBS) were measured before and after one year of romosozumab treatment.
Results
Twenty-five patients in the ROMO group and five in the control group were included in the study. Among patients in the ROMO group, 12 were in the GIOP, 9 in the IOP, and 4 in the PLO subgroups. The mean age was 37.0 years [32.0–42.0], and the median body mass index was 18.8 kg/m
2
[17.5–21.3]. After romosozumab treatment, lumbar spine (LS), femur neck (FN) BMD, and TBS increased from baseline (LSBMD, 12.8% [8.2–19.3],
p
< 0.001; FNBMD, 4.6% [− 0.6–10.7],
p
= 0.016; TBS, 4.1% ± 3.8,
p
< 0.001) in the ROMO group. Patients in both the GIOP and IOP subgroups showed a significant increase in LSBMD, while those in the IOP subgroup demonstrated significant increases in FNBMD.
Conclusion
We demonstrated romosozumab’s efficacy in BMD increment in premenopausal women. Romosozumab may be a potential treatment option for premenopausal women with low bone mass, regardless of etiologies, although further research on fracture risk reduction is warranted.
Publisher
Springer London,Springer Nature B.V
Subject
Absorptiometry, Photon - methods
/ Adult
/ Antibodies, Monoclonal - pharmacology
/ Antibodies, Monoclonal - therapeutic use
/ Bone Density Conservation Agents - pharmacology
/ Bone Density Conservation Agents - therapeutic use
/ Cancellous Bone - drug effects
/ Cancellous Bone - physiopathology
/ Female
/ Femur
/ Femur Neck - physiopathology
/ Glucocorticoids - adverse effects
/ Humans
/ Lumbar Vertebrae - physiopathology
/ Medicine
